Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.80 |
| ▸ | JAK3 | P52333 | 2/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | FES | P07332 | 1/20 | 0.80 |
| ▸ | FER | P16591 | 1/20 | 0.80 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.80 |
| ▸ | TEC | P42680 | 1/20 | 0.80 |
| ▸ | CLK1 | P49759 | 1/20 | 0.80 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.80 |
| ▸ | BTK | Q06187 | 1/20 | 0.80 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28581254 | 0.97 | EGFR (0.94) | EGFRALKJAK3GAKFES | |
| SCHEMBL2724456 | 0.92 | EGFR (1.00) | EGFRALKJAK3GAKFES | |
| SCHEMBL9945477 | 0.92 | EGFR (0.86) | EGFRALKJAK3GAKFES | |
| Rociletinib SCHEMBL29350136 | 0.89 | EGFR (1.00) | EGFRALKJAK3GAKFES | |
| Rociletinib SCHEMBL29448192 | 0.89 | EGFR (1.00) | EGFRALKJAK3GAKFES | |
| Rociletinib SCHEMBL4177736 | 0.89 | EGFR (1.00) | EGFRALKJAK3GAKFES | |
| SCHEMBL9945449 | 0.89 | EGFR (0.82) | EGFRALKJAK3GAKFES | |
| SCHEMBL28589814 | 0.89 | EGFR (0.94) | EGFRALKJAK3GAKFES | |
| Rociletinib SCHEMBL30101824 | 0.88 | EGFR (0.99) | EGFRALKJAK3GAKFES | |
| SCHEMBL28584062 | 0.88 | EGFR (0.80) | EGFRALKJAK3GAKFES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2022-07-14 | — | — | US | disclosed |
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2022-07-14 | — | — | US | disclosed |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2020-09-03 | — | — | US | disclosed |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2020-09-03 | — | — | US | disclosed |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-10-08 | — | — | US | disclosed |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-10-08 | — | — | US | disclosed |
| US-20180353508-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-12-13 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012061299-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434101-B2 | Heterocyclic compounds and uses thereof | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ALK 854/4885JAK3 741/4885 |
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ALK 854/4885JAK3 741/4885 |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ALK 854/4885JAK3 741/4885 |
| US-20180353508-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ALK 854/4885JAK3 741/4885 |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ALK 854/4885JAK3 741/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | EGFR 2849/4885ALK 854/4885JAK3 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.